- Home
- STAA vs PTGX Comparison
STAA vs PTGX Comparison
Compare STAA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAA
- PTGX
- Stock Information
- Founded
- STAA 1982
- PTGX 2006
- Country
- STAA United States
- PTGX United States
- Employees
- STAA N/A
- PTGX N/A
- Industry
- STAA Ophthalmic Goods
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- STAA Health Care
- PTGX Health Care
- Exchange
- STAA Nasdaq
- PTGX Nasdaq
- Market Cap
- STAA 1.4B
- PTGX 3.7B
- IPO Year
- STAA N/A
- PTGX 2016
- Fundamental
- Price
- STAA $27.16
- PTGX $62.14
- Analyst Decision
- STAA Hold
- PTGX Strong Buy
- Analyst Count
- STAA 8
- PTGX 9
- Target Price
- STAA $22.50
- PTGX $70.44
- AVG Volume (30 Days)
- STAA 667.8K
- PTGX 948.7K
- Earning Date
- STAA 10-29-2025
- PTGX 11-06-2025
- Dividend Yield
- STAA N/A
- PTGX N/A
- EPS Growth
- STAA N/A
- PTGX N/A
- EPS
- STAA N/A
- PTGX 0.80
- Revenue
- STAA $224,449,000.00
- PTGX $209,180,000.00
- Revenue This Year
- STAA N/A
- PTGX N/A
- Revenue Next Year
- STAA $27.24
- PTGX $248.17
- P/E Ratio
- STAA N/A
- PTGX $76.66
- Revenue Growth
- STAA N/A
- PTGX N/A
- 52 Week Low
- STAA $13.50
- PTGX $33.31
- 52 Week High
- STAA $38.60
- PTGX $62.17
- Technical
- Relative Strength Index (RSI)
- STAA 56.68
- PTGX 62.68
- Support Level
- STAA $26.98
- PTGX $57.90
- Resistance Level
- STAA $28.13
- PTGX $60.40
- Average True Range (ATR)
- STAA 0.47
- PTGX 2.48
- MACD
- STAA -0.35
- PTGX 0.09
- Stochastic Oscillator
- STAA 12.86
- PTGX 99.22
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.